OakChart

Rapport Therapeutics Inc

RAPPHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 12:13 PM ET

26.45+0.49 (1.87%)
2026-11-11 18:14 CET
Market cap
1,538.90 USD m
Revenue, TTM
20.00 USD m
Net income, TTM
-150.47 USD m
Free cash flow, TTM
-121.18 USD m
EPS diluted, TTM
-3.17
P/E
-
Compare

Price

RAPP against its 20, 50 and 200-day averages
2050200beatmiss
30.0040.0050.004.1M8.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RAPPclose 26.4520-day 26.0250-day 32.81200-day 35.5926.4552w high52w low

50.0% under the 52-week high of 52.93 on 27 Aug 2026. 52-week low 22.06 on 28 Oct 2026. Last 15 sessions, 28.3% high to low

Profile

RAPP
52-week range, 14% of the way up
22.0652.93

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

IndexRUT
Employees84
IPOJun 07, 2024
Beta1.38
ATR, 14d2.19
Rel volume0.30
Short float11.12%
Insider own39.96%
Inst own61.15%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.57B
Enterprise Value1.18B
Income-150.47M
Sales20.00M
Book/sh8.13
Cash/sh6.67
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees84
IPOJun 07, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S78.39
P/B3.25
P/C3.97
P/FCF-
EV/EBITDA-
EV/Sales59.10
Quick Ratio20.07
Current Ratio20.07
Debt/Eq0.02
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.17
EPS next Y-4.26
EPS next Q-0.87
EPS this Y-16.60%
EPS next Y-27.82%
EPS next 5Y-21.15%
EPS past 3/5Y-114.24% -
Sales past 3/5Y- -
EPS Y/Y TTM-17.88%
Sales Y/Y TTM-
EPS Q/Q-18.67%
Sales Q/Q-
EarningsNov 04 BMO
EPS/Sales Surpr.28.61% -

Ownership

Insider Own39.96%
Insider Trans1.83%
Inst Own61.15%
Inst Trans-0.17%
ROA-31.55%
ROE-33.33%
ROIC-37.78%
Gross Margin95.49%
Oper. Margin-838.08%
Profit Margin-752.35%
SMA201.64%
SMA50-19.38%
SMA200-25.69%
Trades-

Technical

Shs Outstand48.09M
Shs Float35.59M
Short Float11.12%
Short Ratio5.26
Short Interest3.96M
52W High52.93 -50.04%
52W Low22.06 19.88%
Volatility7.09% 8.88%
ATR (14)2.19
RSI (14)45.27
Beta1.38
Rel Volume0.30
Avg Volume752.41K
Volume101,626

Performance

Perf Week1.99%
Perf Month-8.77%
Perf Quarter-44.16%
Perf Half Y-30.55%
Perf YTD-12.83%
Perf Year3.71%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price64.21
Prev Close25.96
Price26.45
Change %1.87%

Analyst ratings

latest 10 of 15
DateActionAnalystRating changeTargetImplied
Oct 15, 2026InitiatedWWolfe ResearchOutperform$50+89.1%
Oct 15, 2026InitiatedUUBSBuy$71+168.5%
Oct 06, 2026InitiatedGGuggenheimBuy$65+145.8%
Jul 28, 2026InitiatedWWilliam BlairOutperform
Jun 24, 2026InitiatedLLeerink PartnersOutperform$52+96.6%
May 19, 2026ResumedTTruistBuy$56+111.7%
Apr 10, 2026InitiatedRRaymond JamesStrong Buy$66+149.6%
Feb 02, 2026InitiatedWWells FargoOverweight$43+62.6%
Nov 19, 2025InitiatedBBTIG ResearchBuy$47+77.7%
Sep 16, 2025InitiatedTTruistBuy$44+66.4%

Peers

Mkt cap
TickerCompanyMkt cap
XENEXenon Pharmaceuticals Inc4.06B
PRAXPraxis Precision Medicines Inc9.71B
BHVNBiohaven Ltd2.29B
STOKStoke Therapeutics Inc1.77B
JAZZJazz Pharmaceuticals plc15.70B
HRMYHarmony Biosciences Holdings Inc2.00B
SUPNSupernus Inc6.05B
DNLIDenali Therapeutics Inc3.16B
NPCENeuroPace Inc441.91M
NBIXNeurocrine Biosciences Inc17.38B

Insider trading

latest 14 of 77
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
HEALY JAMESDirectorOct 28 '26Buy21.00969,48020,359,0802,815,707Oct 30 07:32 PM
Ceesay AbrahamChief Executive OfficerOct 21 '26Sale29.162,21064,448450,035Oct 23 04:30 PM
Sanchez RamiroDirectorOct 23 '26Buy27.353,60098,4783,600Oct 23 04:01 PM
Silva Paul MDirectorOct 22 '26Buy27.073,68099,6363,680Oct 22 04:57 PM
Young Wendy B.DirectorOct 22 '26Buy26.393,78999,99213,289Oct 22 04:56 PM
PAUL STEVEN MDirectorOct 22 '26Buy27.2835,714974,27877,380Oct 22 04:56 PM
MARAGANORE JOHNDirectorOct 22 '26Buy26.459,411248,8919,411Oct 22 04:56 PM
Ignelzi Troy A.Chief Financial OfficerOct 21 '26Buy26.105,500143,55015,500Oct 21 05:46 PM
Ceesay AbrahamChief Executive OfficerOct 06 '26Sale32.033,375108,106453,392Oct 08 04:07 PM
Ceesay AbrahamChief Executive OfficerOct 07 '26Sale30.661,14735,167452,245Oct 08 04:07 PM
Abraham N. CeesayOfficerOct 06 '26Proposed Sale31.1539,4701,229,490Oct 06 06:18 PM
Gault CherylChief Operating OfficerSep 30 '26Sale33.1910,000331,856139,914Oct 01 04:30 PM
CHERYL GAULTOfficerSep 30 '26Proposed Sale33.0210,000330,200Sep 30 04:20 PM
Ceesay AbrahamChief Executive OfficerSep 23 '26Sale39.172,21086,565456,767Sep 24 04:05 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IBBiShares Biotechnology ETFAUM: 11.36B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
DFASU.S. Small Cap Portfolio-ETF Class Shares-
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B

News

latest 14 of 154
  • Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update (GlobeNewswire)
  • Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement (GlobeNewswire)
  • Rapport Therapeutics stock tumbles on $350M capital raise (Investing.com) -18.30%
  • Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement (GlobeNewswire)
  • Loading…
  • Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement (GlobeNewswire) +8.72%
  • Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Rises (Investor's Business Daily) -14.67%
  • RAPP Stock Tempers Premarket Gains On Concerns Over Higher Discontinuation Rates In Bipolar Mania Study (Stocktwits)
  • Rapports novel oral drug posts Phase II bipolar win (Clinical Trials Arena)
  • Rapports epilepsy drug finds surprising success in bipolar trial (BioPharma Dive)
  • Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging (Barrons.com)
  • Premarket movers: RTX rises, GE slips following quarterly results (Investing.com)
  • Rapport Therapeutics soars over 50% as bipolar mania drug meets trial goals (Investing.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.840-1.177-0.8400.000.0016
2026Q22026-08-05-1.190-0.963-1.1930.000.0012
2026Q12026-05-07-0.420-0.606-0.42020.007.5010
2025Q42026-03-10-0.720-0.678-0.7190.000.0010
2025Q32025-11-06-0.710-0.775-0.7100.000.008
2025Q22025-08-07-0.750-0.814-0.7540.000.007
2025Q12025-05-08-0.680-0.760-0.6820.000.006
2024Q42025-03-11-0.570-0.640-0.5460.000.005
2024Q32024-11-07-0.500-0.564-0.4800.000.005
2024Q22024-08-08-1.700-0.600-0.4950.000.004
2024Q12024-05-29-1.003--0.6200.00--
2026Q4---0.870--0.0116
2027Q1---0.929--0.009
2027Q2---1.043--0.009
2027Q3---1.124--0.008
2027Q4---1.401--0.008

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-3.780-3.701-2.1410.000.00
2025FY-2.860-2.841-2.8600.000.00
2026FY--3.335--20.01
2027FY--4.263--0.00
2028FY--5.086--0.00
2029FY--5.235--28.37
2030FY--4.218--118.11

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0414010.010.000.10
2026Q4S2026-10-1414000.070.001.00
2026Q4S2026-10-1313000.080.001.00
2026Q4S2026-10-0712000.000.000.00
2026Q4S2026-08-0611000.000.000.00
2026Q4S2026-08-0510000.000.000.00
2026Q4S2026-06-239000.000.000.00
2026Q4S2026-06-188000.000.000.00
2026Q4S2026-05-159000.000.000.00
2026Q4S2026-05-078000.000.000.00
2026Q4S2026-04-087000.000.000.00
2026Q4S2026-03-126000.000.000.00
2026Q4S2026-03-105000.000.000.00
2026Q4S2026-01-304000.000.000.00

Estimate history

EPS, annual-0.291-0.951-2.141-2.863-3.1739
Period2022202320242025TTM
EPS, quarterly-0.48-0.546-0.682-0.754-0.71-0.719-0.42-1.193-0.842
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000020
Period2022202320242025TTM
Sales, quarterly0000002000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual36.57636.57636.5847.77348.088
Period2022202320242025MRQ
Shares, quarterly36.57636.5836.49736.49847.6547.77347.80747.95548.088
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue20.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.901.020.840.110.01
Gross Profit19.10-1.02-0.84-0.11-0.01
Selling, General and Administrative Excl. Other186.71124.0882.2236.0710.35
Research and Development148.7094.7960.9428.009.12
Other Operating Expense0.000.000.000.000.00
Operating Income-167.62-125.10-83.06-36.18-10.37
Interest Expense0.000.000.000.000.28
Unusual Expense0.000.007.391.120.00
Net Income Before Taxes-150.47-111.48-78.31-34.78-10.65
Income Taxes0.000.000.000.010.00
Consolidated Net Income-150.47-111.48-78.31-34.79-10.65
Net Income From Continuing Operations-150.47-111.48-78.31-34.79-10.65
Net Income-150.47-111.48-78.31-34.79-10.65
EPS (Recurring)-3.15-2.86-2.00-0.93-0.29
EPS (Basic, Before Extraordinaries)-3.17-2.86-2.14-0.95-0.29
EPS (Diluted)-3.17-2.86-2.14-0.95-0.29
EBITDA-166.71-124.08-82.22-36.07-10.35
Non-Operating Income (Expense)17.1513.6212.142.530.00
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense27.4918.8610.232.780.56
Price To Sales Ratio80.25----
Gross Margin95.49----
Operating Margin-838.08----
Net Margin-752.35----
Shares Outstanding48.0947.7736.5836.5836.58
Market Capitalization1,538.901,538.90648.87676.30-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.0020.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.200.210.230.270.260.250.240.26
Gross Profit-0.20-0.2119.77-0.27-0.26-0.25-0.24-0.26
Selling, General and Administrative Excl. Other43.8960.5943.9938.2429.7329.2426.8623.26
Research and Development34.3251.4132.7230.2622.2822.6819.5717.20
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-44.09-60.81-24.21-38.51-29.99-29.50-27.11-23.52
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-40.23-56.62-19.86-33.76-26.93-26.73-24.06-19.98
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-40.23-56.62-19.86-33.76-26.93-26.73-24.06-19.98
Net Income From Continuing Operations-40.23-56.62-19.86-33.76-26.93-26.73-24.06-19.98
Net Income-40.23-56.62-19.86-33.76-26.93-26.73-24.06-19.98
EPS (Recurring)-0.84-1.19-0.42-0.72-0.71-0.75-0.68-0.55
EPS (Basic, Before Extraordinaries)-0.84-1.19-0.42-0.72-0.71-0.75-0.68-0.55
EPS (Diluted)-0.84-1.19-0.42-0.72-0.71-0.75-0.68-0.55
EBITDA-43.89-60.59-23.99-38.24-29.73-29.24-26.86-23.26
Non-Operating Income (Expense)3.854.194.364.753.062.763.043.54
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.637.206.965.694.744.394.043.21
Price To Sales Ratio80.2598.9173.90-----
Gross Margin--98.87-----
Operating Margin---121.08-----
Net Margin---99.28-----
Shares Outstanding48.0947.9647.8147.7747.6536.5036.5036.58
Market Capitalization1,538.901,992.951,495.441,446.041,369.57414.98366.06648.87

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments490.64305.38147.5631.16
Short Term Receivables0.000.000.000.00
Inventories0.000.000.000.00
Other Current Assets7.924.423.310.11
Total Current Assets498.56309.80150.8731.27
Net Property, Plant & Equipment12.884.974.000.34
Total Investments and Advances0.000.000.000.00
Intangible Assets---0.00
Other Assets0.980.160.550.00
Total Assets512.43314.93155.4231.60
Short Term Debt Incl. Current Port. of LT Debt2.750.740.670.00
Accounts Payable4.190.000.000.00
Other Current Liabilities12.108.038.131.66
Total Current Liabilities19.058.778.801.66
Long Term Debt8.730.741.480.00
Provision for Risks Charges0.000.000.000.00
Other Liabilities0.000.004.2010.44
Total Liabilities27.789.5114.4812.10
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.00166.5829.57
Common Equity484.65305.43-25.63-10.06
Total Shareholders Equity484.65305.43140.9419.50
Accumulated Minority Interest0.000.000.000.00
Total Equity484.65305.43140.9419.50
Total Liabilities & Stockholders Equity512.43314.93155.4231.60
Book Value Per Share10.158.35-0.70-0.28
Tangible Book Value Per Share10.158.35-0.70-0.28
Full-Time Employees846958-
Price to Book Ratio3.192.012.09-
Return on Assets-26.95-33.30-37.20-
Return on Equity-28.22-35.09-43.36-
Return on Invested Capital-22.60-25.58-24.42-54.61
Quick Ratio26.1735.3417.1418.80
Current Ratio26.1735.3417.1418.80

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-150.47-111.48-78.31-34.79-10.65
Depreciation0.901.020.840.110.01
Other Funds (Non Cash)28.5419.4915.064.845.91
Funds from Operations-121.03-90.97-62.41-29.83-4.73
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital0.183.50-2.422.651.49
Cash from Operating Activities-120.85-87.47-64.83-27.18-3.24
Capital Expenditures-0.33-0.62-2.40-1.64-0.28
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.400.000.000.000.00
Purchase or Sale of Investments-59.79-186.86-167.74-77.220.00
Purchase of Investments-281.51-354.78-377.53-77.220.00
Sale Or Maturity of Investments221.72167.93209.800.000.00
Other Uses0.000.000.000.00-5.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-59.72-187.47-170.14-78.86-5.28
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock3.96270.79221.62145.2731.79
Repurchase of Common Pref Stock-0.01-0.000.00-0.000.00
Sale of Common Pref Stock3.97270.79221.62145.2731.79
Proceedsfrom Stock Options-0.85269.44221.62145.2731.79
Issuance or Reduction of Debt, Net0.000.000.000.007.90
Change in Long Term Debt0.000.000.000.007.90
Issuance of Long Term Debt0.000.000.000.007.90
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.130.00
Other Financing Activities Uses0.000.000.00-0.130.00
Cash from Financing Activities3.96270.79221.62145.1439.69
Net Change in Cash-176.60-4.16-13.3439.0931.16
Free Cash Flow-121.18-88.09-67.23-28.82-3.53
Preferred Dividends (Cash Flow)-0.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments395.13436.18476.89490.64513.13260.55
Short Term Receivables0.170.290.060.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets12.0810.387.757.927.539.69
Total Current Assets407.38446.86484.69498.56520.66270.24
Net Property, Plant & Equipment10.0811.0711.8512.8813.6014.22
Total Investments and Advances0.000.000.000.000.000.00
Other Assets1.091.061.060.981.071.03
Total Assets418.56458.98497.60512.43535.32285.50
Short Term Debt Incl. Current Port. of LT Debt2.332.472.622.752.481.76
Accounts Payable1.722.806.564.193.233.18
Other Current Liabilities16.2623.168.7212.108.606.94
Total Current Liabilities20.3028.4217.9019.0514.3211.88
Long Term Debt7.077.638.198.739.3910.10
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities27.3736.0626.0927.7823.7121.98
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity391.19422.93471.51484.65511.62263.51
Total Shareholders Equity391.19422.93471.51484.65511.62263.51
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity391.19422.93471.51484.65511.62263.51
Total Liabilities & Stockholders Equity418.56458.98497.60512.43535.32285.50
Book Value Per Share8.138.829.8610.1510.747.22
Tangible Book Value Per Share8.138.829.8610.1510.747.22
Full-Time Employees---84--
Price to Book Ratio3.194.223.082.834.111.45
Return on Assets-31.55-36.85-26.83-26.95-22.55-27.96
Return on Equity-33.33-39.96-28.33-28.22-23.41-29.42
Return on Invested Capital-10.10-13.15-4.14-6.84-5.17-9.77
Quick Ratio20.0715.7227.0826.1736.3722.75
Current Ratio20.0715.7227.0826.1736.3722.75

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-40.23-56.62-19.86-33.76-26.93-26.73
Depreciation0.200.210.230.270.260.25
Other Funds (Non Cash)7.888.147.335.195.514.78
Funds from Operations-32.16-48.26-12.30-28.31-21.16-21.70
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-9.476.81-0.773.613.70-3.37
Cash from Operating Activities-41.63-41.45-13.06-24.70-17.46-25.07
Capital Expenditures0.00-0.08-0.09-0.17-0.13-0.02
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.210.190.000.000.000.00
Purchase or Sale of Investments50.8625.4838.03-174.16-56.6422.62
Purchase of Investments-14.39-39.67-30.37-197.07-101.62-12.86
Sale Or Maturity of Investments65.2565.1668.4022.9244.9835.48
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities51.0625.6037.94-174.32-56.7822.60
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.711.410.530.31270.53-0.06
Repurchase of Common Pref Stock0.000.00-0.010.000.000.00
Sale of Common Pref Stock1.711.410.540.31270.53-0.06
Proceedsfrom Stock Options0.00-0.18-0.27-0.40269.90-0.06
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.711.410.530.31270.53-0.06
Net Change in Cash11.14-14.4425.41-198.71196.29-2.54
Free Cash Flow-41.63-41.53-13.15-24.87-17.60-25.09

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.12%4.0M35.6M690.15K
2026-10-1510.59%3.1M28.8M350.77K
2026-09-3011.09%3.2M28.8M380.10K
2026-09-157.81%2.2M28.8M347.34K
2026-08-317.78%2.2M28.7M352.14K
2026-08-147.77%2.2M28.7M354.45K
2026-07-317.84%2.2M28.7M365.22K
2026-07-159.41%2.7M28.6M387.93K
2026-06-307.91%2.3M28.6M357.12K
2026-06-157.90%2.2M28.4M327.45K
2026-05-298.65%2.5M28.4M342.37K
2026-05-158.51%2.4M28.4M346.43K
2026-04-3010.21%3.0M29.9M331.14K
2026-04-1511.60%3.4M29.4M321.61K
2026-03-3113.14%3.8M29.3M341.09K
2026-03-1312.67%3.7M29.3M367.81K
2026-02-2712.02%3.5M29.2M356.09K
2026-02-1311.64%3.4M29.2M368.36K
2026-01-3011.43%3.3M28.8M390.47K
2026-01-159.98%2.9M28.8M387.50K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15.009.0013.5014.304.8691.000.000.983-0.0190.002
call17.506.5011.000.003.9290.000.000.965-0.0300.003
call20.004.108.505.503.1151120.000.927-0.0450.006
call22.502.006.504.002.7968.000.000.846-0.0620.010
call25.000.404.002.001.98443.000.000.642-0.1360.016
call27.500.402.450.601.7511240.000.498-0.1620.017
call30.000.200.450.300.9343721.000.217-0.0640.012
call32.500.050.250.151.05479.000.000.124-0.0500.008
call35.000.000.050.071.0578460.000.057-0.0280.005
call37.500.001.750.051.11015.000.000.030-0.0170.003
call40.000.000.050.081.4655780.000.044-0.0310.004
call42.500.001.950.271.42011.000.000.024-0.0190.002
call45.000.000.100.051.5641,4710.000.022-0.0180.002
call47.500.001.206.901.6925.000.000.021-0.0200.002
call50.000.000.950.221.83755.000.000.020-0.0200.002
call52.500.002.758.301.9381.000.000.019-0.0210.002
call55.000.001.751.152.06110.000.000.018-0.0210.002
call57.500.002.758.202.1644.000.000.017-0.0210.002
call60.000.002.750.052.23729.000.000.017-0.0210.002
call65.000.002.753.582.4251.000.000.016-0.0220.002
call70.000.002.750.102.5794.000.000.015-0.0220.002
call75.000.002.750.002.7270.000.000.014-0.0230.002
put15.000.000.050.051.8374.000.00-0.016-0.0170.002
put17.500.000.100.051.5411,2730.00-0.036-0.0280.003
put20.000.000.200.201.3442,5890.00-0.073-0.0430.006
put22.500.100.400.401.099423200-0.155-0.0600.010
put25.000.551.650.951.423306200-0.365-0.1340.016
put27.501.803.502.601.73710.000.00-0.504-0.1590.017
put30.002.406.005.002.2659330.00-0.783-0.0610.012
put32.504.508.506.572.6661,2660.00-0.877-0.0470.008
put35.006.5011.0012.003.0194.000.00-0.966-0.0130.003
put37.509.0013.508.503.4334.000.00-0.970-0.0130.003
put40.0011.5016.0013.703.6205970.00-0.974-0.0140.003
put42.5014.0018.5011.903.9642.000.00-0.976-0.0140.002
put45.0016.5021.009.804.2100.000.00-0.978-0.0140.002
put47.5019.0023.5011.604.4201.000.00-0.979-0.0140.002
put50.0021.5026.000.004.6150.000.00-0.980-0.0150.002
put52.5024.2028.5015.204.7961.000.00-0.981-0.0150.002
put55.0026.5031.000.004.8210.000.00-0.982-0.0150.002
put57.5029.0033.500.005.1250.000.00-0.983-0.0150.002
put60.0031.5036.0017.005.0720.000.00-0.983-0.0150.002
put65.0036.5041.000.005.5490.000.00-0.984-0.0150.002
put70.0041.6046.000.005.6760.000.00-0.985-0.0150.002
put75.0046.5051.0041.666.0240.000.00-0.986-0.0150.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-10-308-KCurrent report2026-10-28SEC
2026-10-30424B5SEC
2026-10-30424B5SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-28SEC
2026-10-29305B2Application for designation of a new trustee under the Trust Indenture ActSEC
2026-10-28FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-10-28FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-10-28FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-10-28FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-10-27424B5SEC
2026-10-27424B5SEC
2026-10-234Statement of changes in beneficial ownership of securities2026-10-21SEC
2026-10-234Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-21SEC
2026-10-208-KCurrent report2026-10-20SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-06144Filing for proposed sale of securities under Rule 144.SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-30144Filing for proposed sale of securities under Rule 144.SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1022.02M7207.72K3
2026-0900792.92K3
2026-08005.92M6
2026-0700421.50K2
2026-0600743.20K2
2026-050017.22M4
2026-040018.69M6
2026-0300643.48K3
2026-0200567.03K3
2026-0100513.20K3
2025-1200861.32K5
2025-1100639.62K4

Institutional holders

Manager% owned
FMR LLC15.00%
TRV GP V, LLC13.13%
ARCH Venture Management, LLC7.80%
Capital International Investors6.11%
GOLDMAN SACHS GROUP INC6.09%
BlackRock, Inc.5.64%
Sofinnova Investments, Inc.3.98%
JOHNSON & JOHNSON3.72%
Polar Capital Holdings Plc3.36%
BAKER BROS. ADVISORS LP3.23%

Funds

Fund% owned
Fidelity Growth Company Fund4.70%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.06%
iShares Russell 2000 ETF1.67%
Fidelity Growth Company K6 Fund1.44%
Fidelity Series Growth Company Fund1.24%
T. Rowe Price Health Sciences Fund, Inc.1.20%
Select Biotechnology Portfolio0.89%
Fidelity Small Cap Index Fund0.70%
VANGUARD EXTENDED MARKET INDEX FUND0.69%
AB Small Cap Growth Portfolio0.63%

OakChart. RAPP. Cached 15 minutes.